Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unipharma CoROCO:6621 -3.42%72 Days Payable is 144.18 as of Dec. 2025, which is 55% above its 10-year median of 93.29. GuruFocus rates ROCO:6621 with a GF Score™ of 72/100 and a GF Value™ of NT$11.58 (Fairly Valued). The stock has 2 warning signs investors should review. Among 927 Drug Manufacturers companies, Unipharma Co ranks better than 71.2% on this metric.
The historical rank and industry rank for Unipharma Co's Days Payable or its related term are showing as below:
ROCO:6621'
s Days Payable Range Over the Past 10 Years
Min: 33.57 Med: 93.29 Max: 149.8
Current: 137.32
During the past 13 years, Unipharma Co's highest Days Payable was 149.80. The lowest was 33.57. And the median was 93.29.
ROCO:6621's Days Payable is ranked better than 71.2% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ROCO:6621: 137.32
Unipharma Co's Days Payable
increased
from Dec. 2024 (61.76) to Dec. 2025 (144.18).
It may suggest that Unipharma Codelayed paying its suppliers.
Unipharma Co Days Payable Related Terms
Unipharma Co Days Payable Historical Data
* Premium members only.
The historical data trend for Unipharma Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Unipharma Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Unipharma Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unipharma Co (ROCO:6621) has a Days Payable of 144.18 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Unipharma Co and its competitors. This is 55% above median its historical median of 93.29. Over the past decade, Unipharma Co's Days Payable has ranged from 33.57 to 149.80. According to the industry distribution chart, Unipharma Co ranks #267 out of 927 companies in the Drug Manufacturers industry, placing it in the top 28.8%.
Is Unipharma Co's Days Payable too high?
Unipharma Co's current Days Payable of 144.18 is 55% above median its 10-year median of 93.29. Over the past 10 years, this metric has ranged from a low of 33.57 to a high of 149.80. The Drug Manufacturers industry median Days Payable is 90.38. Unipharma Co's value of 144.18 is 59.5% above this industry median. Based on the distribution chart, Unipharma Co ranks #267 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Unipharma Co has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #267 out of 927 companies for Days Payable. This puts Unipharma Co in the upper half of its industry. The industry median Days Payable is 90.38. Unipharma Co's value of 144.18 is 59.5% above this benchmark. Historically, Unipharma Co's own Days Payable has ranged from 33.57 to 149.80 over the past decade. While the company's 10-year median is 93.29 vs. the industry median of 90.38, Unipharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unipharma Co's current Days Payable of 144.18 is 59.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Unipharma Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current Days Payable is 144.18, which is 55% above median its own 10-year median of 93.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.58, compared to a current price of NT$11.30 — trading 2.4% below its estimated fair value. The current Days Payable is 144.18, which is 55% above median its 10-year median of 93.29 and 59.5% above the Drug Manufacturers industry median of 90.38. Unipharma Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current Days Payable is 144.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.30 is trading 2.4% below its estimated GF Value™ of NT$11.58.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
Days Payable: 144.18 (55% above median its 10-year median of 93.29)
GF Value™: NT$11.58 vs. price of NT$11.30 (2.4% below fair value)
Industry Position: 59.5% above the Drug Manufacturers median (#267 of 927)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
72GF Score
Get the complete analysis for ROCO:6621
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 
